Wu J, et al. - Via a retrospective study conducted from January 2015 to December 2017 that included 124 gouty patients with hypercholesterolemia or hypertriglyceridemia who were administered uric acid-lowering therapy (UALT) and who received UALT, researchers examined the impact of UALT on hypercholesterolemia and hypertriglyceridemia. A total of 52, 29 and 43 patients were treated with febuxostat, allopurinol, and benzbromarone, respectively, and their efficiency was compared. Every therapy moderately affected serum cholesterol and triglyceride levels. In patients who did not receive lipid-lowering therapy, febuxostat significantly reduced cholesterol and triglyceride levels. Allopurinol and benzbromarone modestly reduced triglyceride levels; however, cholesterol levels were unaltered. Therefore, it was inferred that in gouty patients, uric acid-lowering therapy benefited hyperlipidemia. In comparison with allopurinol and benzbromarone, febuxostat efficiently improved serum cholesterol and triglyceride levels in patients with gout.